Soluble Interleukin-6 Receptor is a Prognostic Marker for Relapse-Free Survival in Estrogen Receptor-Positive Breast Cancer

By Won Hye Sung   Kim Young Ae   Lee Jun Sang   Jeon Eun Kyoung   An Ho Jung   Sun Der Sheng   Ko Yoon Ho   Kim Jeong Soo  

Cancer Investigation, Vol. 31, Iss. 8, 2013-10 ,pp. : 516-521

Informa Healthcare

Access to resources Recommend Favorite

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

By Masuda Norikazu   Iwata Hiraji   Rai Yoshiaki   Anan Keisei   Takeuchi Toru   Kohno Norio   Takei Hiroyuki   Yanagita Yasuhiro   Noguchi Shinzaburo  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 443-451

Springer Publishing Company

Access to resources Recommend Favorite

Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor–positive breast cancer: the results of a 2-year multicenter open randomized study

By Anan Keisei  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 775-781

Springer Publishing Company

Access to resources Recommend Favorite

Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: A 5-year survival analysis

By  

Oncology Reports, Vol. 32, Iss. 6, 2014-01 ,pp. : 2735-2743

Spandidos Publications

Access to resources Recommend Favorite

Tumor Location of the Lower-Inner Quadrant Is Associated with an Impaired Survival for Women With Early-Stage Breast Cancer

By Sarp Séverine   Fioretta Gérald   Verkooijen Helena   Vlastos Georges   Rapiti Elisabetta   Schubert Hyma   Sappino André-Pascal   Bouchardy Christine  

Annals of Surgical Oncology, Vol. 14, Iss. 3, 2007-03 ,pp. : 1031-1039

Springer Publishing Company

Access to resources Recommend Favorite